Technical Analysis for NTLA - Intellia Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 14.83 1.30% 0.19
NTLA closed up 1.3 percent on Tuesday, September 17, 2019, on 54 percent of normal volume.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical NTLA trend table...

Date Alert Name Type % Chg
Crossed Above 20 DMA Bullish 0.00%
Spinning Top Other 0.00%
Wide Bands Range Expansion 0.00%
Wide Bands Range Expansion 1.30%
20 DMA Resistance Bearish 4.07%
Wide Bands Range Expansion 4.07%
Fell Below 20 DMA Bearish 0.54%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.54%
Wide Bands Range Expansion 0.54%
Crossed Above 20 DMA Bullish -2.50%

Older signals for NTLA ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Intellia Therapeutics Inc., a gene editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, hepatitis B virus, and inborn errors of metabolism; and ex vivo applications of the technology in chimeric antigen receptor T cell and hematopoietic stem cell product candidates. It has a strategic collaboration and license agreement with Novartis focused on the development of new ex vivo CRISPR/Cas9-based therapies. Intellia Therapeutics Inc. was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics Inc. in July 2014. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Biology Immune System Emerging Technologies Molecular Biology Genetics Inborn Errors Of Metabolism Genome Editing Liver Diseases Antitrypsin Deficiency Chimeric Antigen Receptor Cas9 CRISPR Transthyretin Amyloidosis
Is NTLA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 32.95
52 Week Low 11.03
Average Volume 474,450
200-Day Moving Average 15.5524
50-Day Moving Average 16.2932
20-Day Moving Average 14.68
10-Day Moving Average 14.229
Average True Range 0.7791
ADX 22.04
+DI 23.6172
-DI 23.2376
Chandelier Exit (Long, 3 ATRs ) 15.4427
Chandelier Exit (Short, 3 ATRs ) 15.2173
Upper Bollinger Band 17.0315
Lower Bollinger Band 12.3285
Percent B (%b) 0.53
BandWidth 32.036785
MACD Line -0.5216
MACD Signal Line -0.6695
MACD Histogram 0.1479
Fundamentals Value
Market Cap 535.54 Million
Num Shares 36.1 Million
EPS -1.33
Price-to-Earnings (P/E) Ratio -11.15
Price-to-Sales 42.05
Price-to-Book 5.07
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.82
Resistance 3 (R3) 15.80 15.44 15.66
Resistance 2 (R2) 15.44 15.19 15.46 15.60
Resistance 1 (R1) 15.14 15.04 15.29 15.16 15.54
Pivot Point 14.78 14.78 14.86 14.80 14.78
Support 1 (S1) 14.48 14.53 14.63 14.50 14.12
Support 2 (S2) 14.12 14.38 14.14 14.06
Support 3 (S3) 13.82 14.12 14.01
Support 4 (S4) 13.84